Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 9/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796656 | 0.88 | CTSS (0.46) | KMT2ACTSLCTSSCTSKCTSB | |
| SCHEMBL4797750 | 0.85 | CTSS (0.45) | KMT2ACTSLCTSSCTSKSMN1; SMN2 | |
| SCHEMBL4801319 | 0.85 | EPHX2 (0.49) | TSHRKMT2ACTSLCTSSCTSK | |
| SCHEMBL4800895 | 0.84 | CTSL (0.44) | TSHRKMT2ACTSLCTSSCTSK | |
| SCHEMBL4798555 | 0.84 | CTSL (0.44) | KMT2ACTSLCTSSCTSKSMN1; SMN2 | |
| SCHEMBL4800967 | 0.82 | CTSL (0.61) | KMT2ACTSLCTSSCTSK | |
| SCHEMBL4800032 | 0.81 | CTSL (0.43) | KMT2ACTSLCTSSCTSKSMN1; SMN2 | |
| SCHEMBL4796166 | 0.80 | CTSS (0.56) | CTSLCTSSCTSK | |
| SCHEMBL4797862 | 0.79 | CTSS (0.48) | CTSLCTSSCTSK | |
| SCHEMBL4795921 | 0.78 | CTSS (0.47) | CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | TSHR 3750/4885KMT2A 4282/4885CTSL 11/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | TSHR 3750/4885KMT2A 4282/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.